Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice

Vaccine

Volumn 34, Issue 16, 2016, Pages 1927-1935

  Bengtsson, Karin Lövgren ^a   Song, Haifeng ^a   Stertman, Linda ^a   Liu, Ye ^a   Flyer, David C ^a   Massare, Michael J ^a   Xu, Ren Huan ^a   Zhou, Bin ^a   Lu, Hanxin ^a   Kwilas, Steve A ^b   Hahn, Timothy J ^a   Kpamegan, Eloi ^a   Hooper, Jay ^b   Carrion, Ricardo ^c   Glenn, Gregory ^a   Smith, Gale ^a  

^a NOVAVAX INC   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Ebola virus; Glycoprotein; Matrix M adjuvant; Nanoparticle; Vaccine

Indexed keywords

ALUMINUM PHOSPHATE; EBOLA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MAKONA VIRUS GLYCOPROTEIN; MATRIX M; NANOPARTICLE; NEUTRALIZING ANTIBODY; SAPONIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ZAIRE EBOLAVIRUS GLYCOPROTEIN; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENTIATION; EBOLA HEMORRHAGIC FEVER; FOLLICULAR HELPER T CELL; GERMINAL CENTER; HELPER CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; MURINE MODEL; NONHUMAN; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROTECTION; SPLEEN; VIRUS GENE; VIRUS NEUTRALIZATION; VIRUS STRAIN; ZAIRE EBOLAVIRUS; ANIMAL; BLOOD; CYTOLOGY; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EBOLA VACCINES; EBOLAVIRUS; GERMINAL CENTER; HEMORRHAGIC FEVER, EBOLA; MICE; NANOPARTICLES; VIRAL ENVELOPE PROTEINS;

EID: 84961050529     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.033     Document Type: Article

References (46)

1. Cooper C.L., Bavari S. A race for an Ebola vaccine: promises and obstacles. Trends Microbiol 2015, 23:65-66.
2. Marzi A., Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines 2014, 13:521-531.
3. Radosević K., Rodriguez A., Mintardjo R., Tax D., Bengtsson K.L., Thompson C., et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 2008, 26:3640-3646.
4. + cells and strong antibody responses in mice. Vaccine 2009, 27:7367-7376.
5. Cox R.J., Pedersen G., Madhun A.S., Svindland S., Sævik M., Breakwell L., et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 2011, 29:8049-8059.
6. Pedersen G., Major D., Roseby S., Wood J., Madhun A.S., Cox R.J. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respir Viruses 2011, 5:426-437.
7. Skoberne M., Cardin R., Lee A., Kazimirova A., Zielinski V., Garvie D., et al. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs. J Virol 2013, 87:3930-3942.
8. + T cell responses in man. Hum Vaccine Immunother 2014, 10:2408-2416.
9. Pedersen G.K., Madhun A.S., Breakwell L., Hoschler K., Sjursen H., Pathirana R.D., et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J Infect Dis 2012, 206:158-166.
10. Magnusson S.E., Reimer J.M., Karlsson K.H., Lilja L., Bengtsson K.L., Stertman L. Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 2013, 31:1725-1733.
11. Reimer J.M., Karlsson K.H., Lövgren-Bengtsson K., Magnusson S.E., Fuentes A., Stertman L. Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS ONE 2012, 7(7):e41451. 10.1371/journal.pone.0041451.
12. Lövgren-Bengtsson K.L., Karlsson K.H., Magnusson S.E., Reimer J.M., Stertman L. Matrix-M adjuvant: enhancing immune responses by 'setting the stage' for the antigen. Expert Rev Vaccines 2013, 12:821-823.
13. Koraka P., Bosch B.J., Cox M., Chubet R., Amerongen G.V., Lövgren-Bengtsson K., et al. A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice. Vaccine 2014, 32:4644-4650.
14. ClinicalTrials.gov. A(H7N9) VLP Antigen Dose-Ranging Study with Matrix-M1™ Adjuvant. Available: 〈https://clinicaltrials.gov/ct2/show/NCT02078674?term=Matrix-M1+Adjuvant&rank=1〉.
15. Kreil T.R. Treatment of Ebola virus infection with antibodies from reconvalescent donors. Emerg Infect Dis 2015, 21:521-523.
16. Takada A., Ebihara H., Jones S., Feldmann H., Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2007, 25:993-999.
17. Marzi A., Yoshida R., Miyamoto H., Ishijima M., Suzuki Y., Higuchi M., et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE 2012, 7(4):e36192. 10.1371/journal.pone.0036192.
18. Audet J., Wong G., Wang H., Lu G., Gao G.F., Kobinger G., et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep 2014, 4(Nov):6881. 10.1038/srep06881.
19. Qiu X., Wong G., Audet J., Bello A., Fernando L., Alimonti J.B., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514:47-53.
20. Bishop B.M. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother 2015, 49:196-206.
21. Marzi A., Engelmann F., Feldmann F., Haberthur K., Shupert W.L., Brining D., et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci USA 2013, 110:1893-1898.
22. Stanley D.A., Honko A.N., Asiedu C., Trefry J.C., Lau-Kilby A.W., Johnson J.C., et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against Ebola virus challenge. Nat Med 2014, 20:1126-1129.
23. + T cells in immunity to viruses. Nat Rev Immunol 2012, 12:136-148.
24. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
25. Ye L., Yang C. Development of vaccines for prevention of Ebola virus infection. Microbes Infect 2015, 17:98-108.
26. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007, 196(Suppl 2):S430-S437.
27. Martins K.A., Steffens J.T., van Tongeren S.A., Wells J.B., Bergeron A.A., Dickson S.P., et al. Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation. PLoS ONE 2014, 9(2):e89735. 10.1371/journal.pone.0089735.
28. Hahn T.J., Webb B., Kutney J., Fix E., Nidel N., Wong J., et al. Rapid manufacture and release of a GMP batch of Zaire ebolavirus glycoprotein vaccine made using recombinant baculovirus-Sf9 insect cell culture technology. BioProcess J 2015, 14:6-14.
29. Lovgren K., Morein B. The requirement of lipids for the formation of immunostimulating complexes (Iscoms). Biotechnol Appl Biochem 1988, 10:161-172.
30. Bente D., Gren J., Strong J.E., Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2009, 2:12-17.
31. Kwilas S., Kishimori J.M., Josleyn M., Jerke K., Ballantyne J., Royals M., et al. A hanta virus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates. Curr Gene Ther 2014, 14:200-210.
32. Smith G., Raghunandan R., Wu Y., Liu Y., Massare M., Nathan M., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS ONE 2012, 7(11):e50852. 10.1371/journal.pone.0050852.
33. Blaney J.E., Marzi A., Willet M., Papaneri A.B., Wirblich C., Feldmann F., et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog 2013, 9(5):e1003389. 10.1371/journal.ppat.1003389.
34. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012, 119:5640-5649.
35. Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014, 5:520. 10.3389/fimmu.2014.00520.
36. Wilson J.A., Hevey M., Bakken R., Guest S., Bray M., Schmaljohn A.L., et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 2000, 287:1664-1666.
37. Qui X., Wong G., Fernando L., Audet J., Bello A., Strong J., et al. mAbs and Ad-vectored IFN-(therapy rescue Ebola-infected nonhuman primates when administered after the detection of Viremia and symptoms. Sci Transl Med 2013, 5(October):207ra143. 10.1126/scitranslmed.3006605.
38. Choi J.H., Jonsson-Schmunk K., Qiu X., Shedlock D.J., Strong J., Xu J.X., et al. A single dose respiratory recombinant adenovirus-based vaccine provides long-term protection for non-human primates from lethal Ebola infection. Mol Pharm 2014, (Nov). dx.doi.org/10.1021/mp500646d.
39. Liew F.Y., Li Y., Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 1990, 145:4306-4310.
40. Chan J., Xing Y., Magliozzo R.S., Bloom B.R. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992, 175:1111-1122.
41. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
42. Pedersen G.K., Höschler K., Øie Solbak S.M., Bredholt G., Pathirana R.D., Afsar A., et al. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine 2014, 32:4550-4557.
43. Bachmann M.F. The role of germinal centers for antiviral B cell responses. Immunol Res 1998, 17:329-344.
44. Hu J., Havenar-Daughton C., Crotty S. Modulation of SAP dependent T: B cell interactions as a strategy to improve vaccination. Curr Opin Virol 2013, 3:363-370.
45. Qi H., Chen X., Chu C., Lu P., Xu H., Yan J. Follicular T-helper cells: controlled localization and cellular interactions. Immunol Cell Biol 2014, 92:28-33.
46. Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity 2014, 41:529-542.